Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Research and development 2,087 1,640
Selling, general and administrative (including $447 and $14,296 expense from stock compensation granted to officers, employees and directors during the three months ended March 31, 2022 and 2021, respectively) 3,355 27,362
Loss from Operations 5,442 29,002
Other (Income) Expense    
Interest income (8)
Interest expense 696
Change in fair value of derivative liability (18) (21)
Unrealized loss on marketable securities 24
Total Other (Income) Expense (2) 675
Net Loss $ (5,440) $ (29,677)
Net loss per share - basic and diluted $ (0.17) $ (1.83)
Weighted average common shares outstanding - basic and diluted 32,486,116 16,239,938